ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.60
0.71%
US Tech 100
19,636.04
0.55%
S&P 500
5,770.20
0.55%
US Dollar vs CAD
1.43715
0.00%
Bitcoin
84,423.10
-2.01%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Kazia Therapeutics Ltd (KZIA)

  7. Kazia Therapeutics Ltd (KZIA) News

KZIA

Kazia Therapeutics (KZIA)

Kazia Therapeutics Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KZIA
DateTimeSourceHeadlineSymbolCompany
02/21/20255:33AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
02/20/20253:55PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
02/20/20253:53PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
02/20/20253:51PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
02/20/20257:46AMPR Newswire (US)Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's DiseaseNASDAQ:KZIAKazia Therapeutics Ltd
02/05/202511:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
02/05/20253:39PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
02/03/20257:36AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
01/30/20253:31PMEdgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:KZIAKazia Therapeutics Ltd
01/30/20257:05AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
01/30/20257:02AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
01/30/20256:57AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
01/30/20256:30AMPR Newswire (US)Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancerNASDAQ:KZIAKazia Therapeutics Ltd
01/17/20253:30PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:KZIAKazia Therapeutics Ltd
01/16/20259:40AMEdgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KZIAKazia Therapeutics Ltd
01/14/20253:00PMPR Newswire (US)Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
01/13/20257:07AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
01/13/20257:05AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
01/13/20257:03AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
01/13/20257:00AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KZIAKazia Therapeutics Ltd
01/10/20258:58AMPR Newswire (US)Kazia Therapeutics Announces $2.0 Million Registered Direct OfferingNASDAQ:KZIAKazia Therapeutics Ltd
12/31/20247:49AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
12/31/20247:46AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
12/31/20247:43AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
12/31/20247:00AMPR Newswire (US)Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDANASDAQ:KZIAKazia Therapeutics Ltd
12/11/20247:58AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:KZIAKazia Therapeutics Ltd
12/11/20247:00AMPR Newswire (US)Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer SymposiumNASDAQ:KZIAKazia Therapeutics Ltd
12/03/20243:38PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
12/03/20243:33PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KZIAKazia Therapeutics Ltd
12/02/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KZIAKazia Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:KZIA

Your Recent History

BIT
F16710
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads